Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29212477 | 0.78 | AAK1 (0.62) | AAK1ALDH1A1TDP1LMNAMAPT | |
| SCHEMBL6367662 | 0.78 | AAK1 (0.51) | AAK1ALDH1A1LMNAL3MBTL1PDE4B | |
| SCHEMBL30184533 | 0.78 | AAK1 (0.62) | AAK1ALDH1A1TDP1LMNAMAPT | |
| SCHEMBL4814398 | 0.75 | AAK1 (0.51) | AAK1ALDH1A1MAPTHPGDGAA | |
| SCHEMBL15507073 | 0.75 | CASP6 (0.53) | AAK1ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL3400235 | 0.74 | ALDH1A1 (0.59) | ALDH1A1TDP1LMNAL3MBTL1PDE4B | |
| SCHEMBL5557695 | 0.74 | ALDH1A1 (0.53) | ALDH1A1TDP1LMNAL3MBTL1MAPT | |
| SCHEMBL6016410 | 0.73 | ALDH1A1 (0.49) | ALDH1A1TDP1LMNAL3MBTL1PDE4B | |
| SCHEMBL1287837 | 0.73 | ALDH1A1 (0.74) | ALDH1A1TDP1L3MBTL1HPGDGAA | |
| SCHEMBL30535903 | 0.73 | ALDH1A1 (0.74) | ALDH1A1TDP1L3MBTL1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560462-B2 | Compounds useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20080214573-A1 | Compounds Useful for Inhibiting Chk1 | ICOS CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1768977-A2 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| WO-2006014359-A2 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
| US-6884801-B1 | Imidazoline derivatives as alpha-1A adrenoceptor ligands | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-26 | — | — | US | disclosed |
| EP-1175406-A1 | IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066563-A1 | IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2000-11-09 | — | — | WO | disclosed |
| US-4514214-A | Herbicidal sulfamates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
| US-4475944-A | PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-09 | — | — | US | disclosed |
| EP-0096593-A2 | Herbicidal sulfamates | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214573-A1 | Compounds Useful for Inhibiting Chk1 | ORC3, MCM3, CHEK1 | AAK1 3834/4885ALDH1A1 4480/4885TDP1 672/4885 |
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | AAK1 1161/4885ALDH1A1 1541/4885TDP1 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.